Responsible Research and Innovation Framework, the Nagoya Protocol and Other European Blue Biotechnology Strategies and Regulations: Gaps Analysis and Recommendations for Increased Knowledge in the Marine Biotechnology Community

Marine Drugs

Susana P. Gaudêncio¹  Marlen I. Vasquez²  Christiana Tourapi²  Belma Kalamujić Stroil³  Céline Rebours⁴  Lucie Novoveska⁵  Xenia Theodotou Schneider⁶ 

[1] Associate Laboratory i4HB, Institute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University Lisbon, 2819-516 Caparica, Portugal;Department of Chemical Engineering, Cyprus University of Technology, Limassol 3036, Cyprus;Institute for Genetic Engineering and Biotechnology, University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina;Møreforsking AS, 6021 Ålesund, Norway;Ocean4Biotech, Edinburgh EH12 5AD, UK;XPRO Consulting Limited, Strovolos 2021, Cyprus;

关键词: marine biotechnology;    blue biotechnology;    sustainable blue economy;    convention on biological diversity;    Nagoya Protocol;    Responsible Research and Innovation (RRI);   

DOI  :  10.3390/md20050290

来源: DOAJ

【 摘 要 】

As the quest for marine-derived compounds with pharmacological and biotechnological potential upsurges, the importance of following regulations and applying Responsible Research and Innovation (RRI) also increases. This article aims at: (1) presenting an overview of regulations and policies at the international and EU level, while demonstrating a variability in their implementation; (2) highlighting the importance of RRI in biodiscovery; and (3) identifying gaps and providing recommendations on how to improve the market acceptability and compliance of novel Blue Biotechnology compounds. This article is the result of the work of the Working Group 4 “Legal aspects, IPR and Ethics” of the COST Action CA18238 Ocean4Biotech, a network of more than 130 Marine Biotechnology scientists and practitioners from 37 countries. Three qualitative surveys (“Understanding of the Responsible Research and Innovation concept”, “Application of the Nagoya Protocol in Your Research”, and “Brief Survey about the experiences regarding the Nagoya Protocol”) indicate awareness and application gaps of RRI, the Nagoya Protocol, and the current status of EU policies relating to Blue Biotechnology. The article categorises the identified gaps into five main categories (awareness, understanding, education, implementation, and enforcement of the Nagoya Protocol) and provides recommendations for mitigating them at the European, national, and organisational level.

【 授权许可】

Unknown